Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABVC NASDAQ:ANEB NASDAQ:CLSD OTCMKTS:NICXF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVCABVC BioPharma$3.52-1.4%$2.10$0.40▼$5.48$60.62M0.37358,040 shs402,997 shsANEBAnebulo Pharmaceuticals$1.60+1.9%$1.32$0.80▼$3.08$64.50M-0.9819,582 shs37,612 shsCLSDClearside Biomedical$0.84+1.0%$0.82$0.70▼$1.65$64.30M2.05359,663 shs61,693 shsNICXFNicox$0.25$0.25$0.25▼$0.28$17.23M0.29N/AN/A7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVCABVC BioPharma-1.40%-24.79%+80.51%+311.70%+345.51%ANEBAnebulo Pharmaceuticals+1.91%-8.05%+1.27%+58.42%-33.61%CLSDClearside Biomedical+1.04%-5.00%+4.96%-2.79%-31.48%NICXFNicox0.00%0.00%0.00%0.00%-43.18%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABVCABVC BioPharma0.3939 of 5 stars0.03.00.00.02.50.80.0ANEBAnebulo Pharmaceuticals2.7163 of 5 stars3.53.00.00.03.81.70.0CLSDClearside Biomedical2.0629 of 5 stars3.53.00.00.03.30.00.0NICXFNicoxN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABVCABVC BioPharma 0.00N/AN/AN/AANEBAnebulo Pharmaceuticals 3.00Buy$5.50243.75% UpsideCLSDClearside Biomedical 3.00Buy$4.75468.18% UpsideNICXFNicox 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest NICXF, CLSD, ANEB, and ABVC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/23/2025CLSDClearside BiomedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.00 ➝ $5.005/16/2025CLSDClearside BiomedicalJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$5.00 ➝ $5.005/15/2025ANEBAnebulo PharmaceuticalsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.00 ➝ $3.005/15/2025CLSDClearside BiomedicalNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$4.00 ➝ $3.00(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABVCABVC BioPharma$510K117.20N/AN/A$0.06 per share58.67ANEBAnebulo PharmaceuticalsN/AN/AN/AN/A$0.15 per shareN/ACLSDClearside Biomedical$1.66M39.14N/AN/A($0.51) per share-1.64NICXFNicox$5.52M3.12N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABVCABVC BioPharma-$4.90M-$0.13N/A∞N/A-963.46%-29.62%-14.08%8/13/2025 (Estimated)ANEBAnebulo Pharmaceuticals-$8.20M-$0.26N/A∞N/AN/A-90.11%-84.53%9/23/2025 (Estimated)CLSDClearside Biomedical-$34.35M-$0.41N/AN/AN/A-818.57%N/A-114.23%8/11/2025 (Estimated)NICXFNicox-$29.25MN/A0.00∞N/AN/AN/AN/AN/ALatest NICXF, CLSD, ANEB, and ABVC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025CLSDClearside Biomedical-$0.12N/AN/AN/A$0.50 millionN/A5/14/2025Q1 2025CLSDClearside Biomedical-$0.12-$0.11+$0.01-$0.11$0.20 million$2.33 million5/13/2025Q3 2025ANEBAnebulo Pharmaceuticals-$0.05-$0.04+$0.01-$0.04N/AN/A4/30/2025Q4 2024ABVCABVC BioPharmaN/A-$0.06N/A-$0.06N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABVCABVC BioPharmaN/AN/AN/AN/AN/AANEBAnebulo PharmaceuticalsN/AN/AN/AN/AN/ACLSDClearside BiomedicalN/AN/AN/AN/AN/ANICXFNicoxN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABVCABVC BioPharmaN/A0.220.22ANEBAnebulo PharmaceuticalsN/A25.2925.29CLSDClearside BiomedicalN/A3.193.19NICXFNicoxN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABVCABVC BioPharma11.38%ANEBAnebulo Pharmaceuticals28.40%CLSDClearside Biomedical18.75%NICXFNicoxN/AInsider OwnershipCompanyInsider OwnershipABVCABVC BioPharma17.10%ANEBAnebulo Pharmaceuticals80.60%CLSDClearside Biomedical6.20%NICXFNicoxN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABVCABVC BioPharma3016.98 million14.08 millionNot OptionableANEBAnebulo Pharmaceuticals441.09 million7.97 millionNot OptionableCLSDClearside Biomedical3077.71 million72.89 millionOptionableNICXFNicox2868.92 millionN/ANot OptionableNICXF, CLSD, ANEB, and ABVC HeadlinesRecent News About These CompaniesNicox and Kowa Sign Key Agreement worth up to €191.5 million for Exclusive Rights to Glaucoma Treatment NCX 470 in U.S. and all Unlicensed Territories2 hours ago | taiwannews.com.twTNicox S.A. (NICXF) Stock Price, Quote, News & AnalysisJuly 1, 2025 | seekingalpha.comNicox completes phase 3 Denali trial of NCX 470 in open-angle glaucoma or ocular hypertensionJune 30, 2025 | ophthalmologytimes.comONicox Announces Last Patient Completes the NCX 470 Denali Phase 3 Clinical TrialJune 30, 2025 | manilatimes.netMNicox: Notice of the Ordinary and Extraordinary Shareholders’ Meeting on June 27, 2025 and appointment of an ad hoc representativeJune 6, 2025 | santelog.comSNICOX SA: Nicox Announces up to €3 million in Milestone Payments from Kowa in 2025 as NCX 470 Prepares to Enter Phase 3 Clinical Trials in JapanMay 27, 2025 | finanznachrichten.deNicox Announces up to €3 million in Milestone Payments from Kowa in 2025 as NCX 470 Prepares to Enter Phase 3 Clinical Trials in JapanMay 27, 2025 | finance.yahoo.comNicox releases results from Whistler phase 3b trial in IOP lowering eye dropsMay 15, 2025 | ophthalmologytimes.comONicox Announces Results of the Exploratory Whistler Phase 3b Glaucoma TrialMay 14, 2025 | finance.yahoo.comNicOx S.A.May 10, 2025 | barrons.comNicox Provides Full Year 2024 Financial ResultsApril 30, 2025 | finance.yahoo.comNicox announces last patient completed final visit in Whistler Phase 3b clinical trialMarch 24, 2025 | ophthalmologytimes.comONICOX SA: Nicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler Glaucoma TrialMarch 19, 2025 | finanznachrichten.deNicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler Glaucoma TrialMarch 19, 2025 | markets.businessinsider.comNicox presents new analysis from the NCX 470 Mont Blanc trialMarch 7, 2025 | thepharmaletter.comTNICOX SA: Nicox Extends Cash Runway into Q4 2025March 6, 2025 | finanznachrichten.deNicox Presents New Analysis from the NCX 470 Mont Blanc Trial and Provides Development UpdateMarch 3, 2025 | markets.businessinsider.comNicox Announces Scientific Presentation and Conference Attendance in H1 2025January 29, 2025 | markets.businessinsider.comNiconico's Mature Illustration Service Niconico Shunga to End ServiceJanuary 18, 2025 | animenewsnetwork.comANiconico Shunga Latest Japanese Retailer to Shutter Because of “Current Social Environment”January 18, 2025 | otakuusamagazine.comONew MarketBeat Followers Over TimeMedia Sentiment Over TimeNICXF, CLSD, ANEB, and ABVC Company DescriptionsABVC BioPharma NASDAQ:ABVC$3.52 -0.05 (-1.40%) Closing price 07/16/2025 04:00 PM EasternExtended Trading$3.60 +0.08 (+2.27%) As of 07:28 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.Anebulo Pharmaceuticals NASDAQ:ANEB$1.60 +0.03 (+1.91%) Closing price 07/16/2025 04:00 PM EasternExtended Trading$1.61 +0.01 (+0.63%) As of 07/16/2025 04:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.Clearside Biomedical NASDAQ:CLSD$0.84 +0.01 (+1.04%) Closing price 07/16/2025 04:00 PM EasternExtended Trading$0.80 -0.04 (-4.55%) As of 07:33 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.Nicox OTCMKTS:NICXF$0.25 0.00 (0.00%) As of 07/15/2025Nicox S.A. operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. Its lead product candidate is NCX 470, a novel nitric oxide-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial. The company is also developing NCX 4251, a novel patented ophthalmic suspension of fluticasone propionate nanocrystals that is in Phase 2b clinical trial for the treatment of dry eye disease; and NCX 1728, an NO-donating Phosphodiesterase-5 inhibitor, which is in preclinical evaluation. It offers VYZULTA, a latanoprostene bunod ophthalmic solution to treat patients with open-angle glaucoma or ocular hypertension; and ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis. The company was incorporated in 1996 and is headquartered in Valbonne, France. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AMD Just Triggered a Signal Traders Can’t Ignore JNJ’s Stock Price Is Back in Rally Mode—The Time to Buy Is Now This ASML Dip Could Be Gone Before You Know It—Don’t Miss Out Rocket Lab Gets New Street-High Price Target from Citi Super Micro Stock May Benefit as Cooling Demand Takes Off Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings Salesforce Stock Set for 30% Upside to Reach New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
